Burning Rock Biotech Leads The Charge With 2 Other US Penny Stocks

In This Article:

As the U.S. markets continue to enjoy a post-election rally, with major indices like the S&P 500 and Dow Jones Industrial Average reaching new record highs, investors are exploring diverse opportunities across various sectors. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite their somewhat outdated terminology. These stocks can offer growth potential at lower price points when backed by strong financials and solid fundamentals, providing intriguing opportunities for investors looking beyond the usual market giants.

Top 10 Penny Stocks In The United States

Name

Share Price

Market Cap

Financial Health Rating

BAB (OTCPK:BABB)

$0.8479

$5.86M

★★★★★★

LexinFintech Holdings (NasdaqGS:LX)

$3.91

$590.24M

★★★★★★

QuantaSing Group (NasdaqGM:QSG)

$3.08

$161.01M

★★★★★★

RLX Technology (NYSE:RLX)

$1.65

$2.03B

★★★★★★

Better Choice (NYSEAM:BTTR)

$2.10

$4.09M

★★★★★★

ZTEST Electronics (OTCPK:ZTST.F)

$0.2723

$9.41M

★★★★★★

Golden Growers Cooperative (OTCPK:GGRO.U)

$4.50

$69.71M

★★★★★★

PHX Minerals (NYSE:PHX)

$3.50

$131.24M

★★★★★☆

CBAK Energy Technology (NasdaqCM:CBAT)

$1.10

$97.13M

★★★★★☆

So-Young International (NasdaqGM:SY)

$1.25

$86.74M

★★★★☆☆

Click here to see the full list of 748 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Burning Rock Biotech

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Burning Rock Biotech Limited focuses on developing and selling cancer therapy selection tests in the People's Republic of China, with a market cap of $34.47 million.

Operations: No specific revenue segments have been reported for Burning Rock Biotech Limited.

Market Cap: $34.47M

Burning Rock Biotech, with a market cap of US$34.47 million, is navigating challenges typical for penny stocks. The company remains unprofitable and pre-revenue, but it benefits from a seasoned management team averaging 8.7 years in tenure and is debt-free. Recent strategic advancements include the approval of their LungCure CDx by China's NMPA, marking significant progress in precision oncology solutions for lung cancer. Despite delisting from the London Stock Exchange due to low trading volumes, its Nasdaq listing remains active. Executive changes indicate ongoing adjustments within its financial leadership structure amidst these developments.

NasdaqGM:BNR Debt to Equity History and Analysis as at Nov 2024
NasdaqGM:BNR Debt to Equity History and Analysis as at Nov 2024

Caesarstone

Simply Wall St Financial Health Rating: ★★★★☆☆